Extended Data Fig. 3: 3P10 reverses tumor-induced tissue and body weight loss in GDF15 expressing Patient Derived Xenograft (PDX) and syngeneic mouse models.
From: Antibody-mediated inhibition of GDF15–GFRAL activity reverses cancer cachexia in mice
a-c, Quantification of serum GDF15 from HT1080 (a), syngeneic (b) and patient derived xenograft (c) tumor-bearing mice. Data represent mean ± s.e.m. In (a) data represent n = 6 mice/group. In (c) data represent n = 10 for non-tumor bearing (NTB), n = 6 for gastric, n = 9 for ovarian and n = 12 for liver PDX models. d,e Tumor growth measured by caliper of KLN205 and Ovarian PDX shown in Fig. 2e,f. n = 10 per group. f-i, Change in body weight and tumor volume of syngeneic RENCA (f) and B16Bl6 models (g), and gastric (h) and liver (i) PDX models treated with IgG (black) or 3P10 (blue). Data represent mean ± s.e.m. Data represent n = 10 mice/group for (f,g), n = 20 mice/group for (h) and n = 12 mice/group for (i). Numbers above indicate p-values calculated by two-sided t-test. Body weight (BW) was calculated by subtracting the estimated tumor weight (1 g = 1000mm3) from the total, measured body weight to account for variability in tumor size. j, Tissue weights measured from gastric and ovarian PDX tumor models at end of study. Center values indicate mean. Data represent n = 20/group for gastric and n = 9 for ovarian PDX models. Numbers above indicate p-values calculated by two-sided t-test. k, Body weight of normal chow mice (n = 8 per group) treated weekly with IgG1 or 3P10 antibody. Data represent mean +/− s.e.m. All antibodies were dosed at 3 mg/kg in tumor-bearing mice at the times depicted by the arrowheads.
